Research programme: glycogen storage disease type I therapeutics - Prime Medicine
Latest Information Update: 09 Sep 2024
At a glance
- Originator Prime Medicine
- Class Gene therapies
- Mechanism of Action SLC37A4 protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glycogen storage disease type I
Most Recent Events
- 08 Aug 2024 Preclinical trials in Glycogen storage disease type I in USA (IV) before August 2024